Physician
Neurology
Dr. Ali K. Choucair, MD
|
|
Give Review
Ali K. Choucair, MD practices Neurology. He received 9 awards: "CMS Meaningful Use Stage 1 Certification", "Leading Physician of the World", "Award for Excellence in Quality of Life Research. "Clinical Utility of Quality of Life and symptom assessment as prognostic factors for survival and measures of treatment effects on RTOG 0525"", "Americas Top Physicians", "Physician's Recognition Award", "Phi Lambda Epsilon", "Recipient of a stipend", "President's Honor Roll" and "Phi Theta Kappa". Choucair is also published. He has 24 publications published. The lastest publication: "Quality of life and neuropsychological evaluation for patients with malignant astrocytomas: RTOG 91-14. Radiation Therapy Oncology Group.' Doctor Ali K. Choucair, MD is registered with Medicare.
Publications
- Management of Low-Grade Gliomas-A Review of Patient Perceived Quality of Life and Neurocognitive Outcome.
- Net Clinical Benefit Analysis of Radiation Therapy Oncology Group 0525: A Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide...
- Memantine for the prevention of cognitive dysfunction in patients receiving whole-Brain radiotherapy: a randomized, double-blind, placebo-controlled trial.
- RTOG 0211: A Phase 1/2 Study of Radiation Therapy With Concurrent Gefitinib for Newly Diagnosed Glioblastoma Patients.
- Implementing patient-reported outcomes assessment in clinical practice: a review of the options and considerations.
- Quality of life in oncology with emphasis upon neuro-oncology.
- Phase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme: RTOG protocol BR-0021.
- Quality of life measures as a preliminary clinical indicator in patients with primary Brain tumors.
- Prognostic value of H-MLH1 after adjusting for RPA class in GBM patients.
- A phase II trial of accelerated radiotherapy using weekly stereotactic conformal boost for supratentorial glioblastoma multiforme: RTOG 0023.
- Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic Gliomas.
- Phase I study pilot arms of radiotherapy and carmustine with temozolomide for anaplastic Astrocytoma (Radiation Therapy Oncology Group 9813): implications for studies ...
- Quality of life and neuropsychological evaluation for patients with malignant Astrocytomas: RTOG 91-14. Radiation Therapy Oncology Group.
- Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade Gliomas.
- Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N''-cyclohexyl-N-nitrosurea, vincristine...
- Phase I-II study of eflornithine and mitoguazone combined in the treatment of recurrent primary Brain tumors.
- Radiation Therapy Oncology Group. Research Plan 2002-2006. Brain Tumor Committee.
- Recurrent malignant Gliomas: survival following interstitial brachytherapy with high-activity iodine-125 sources.
- Phase II study of combined carmustine, 5-fluorouracil, hydroxyurea, and 6-mercaptopurine (BFHM) for the treatment of malignant Gliomas.
- Development of multiple lesions during radiation therapy and chemotherapy in patients with Gliomas.
- Risk of intraCranial hemorrhage in glioma patients receiving anticoagulant therapy for venous thromboembolism.
- Radiation Therapy Oncology Group. Research Plan 2002-2006. Outcomes Committee.
- Proposals for evaluation of toxic effects associated with treatment of Gliomas: a call for action.
Schools
University Of Calgary Faculty Of Medicine
Foothills Hospital
University Of California
Procedures Preformed
- EEG (Electroencephalogram)
- EMG (Electromyography)
Conditions Treated
- Alzheimer's Disease
- Ataxia
- Bell's Palsy
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- View All
Doctors Specialties
- Neuro-Oncology
- Neurology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
- Leading Physician of the World
- Award for Excellence in Quality of Life Research. "Clinical Utility of Quality of Life and symptom assessment as prognostic factors for survival and measures of treatment effects on RTOG 0525"
- America’s Top Physicians
- Physician's Recognition Award
- Phi Lambda Epsilon
- Recipient of a stipend
- President's Honor Roll
- Phi Theta Kappa
Education
-
UCSF -
University of Utah -
University of Calgary Faculty of Medicine
Hospital
-
Norton Hospital
Drug Facts
| NPI NUMBER | 1063426971 | |
| NPPES Provider LastName | CHOUCAIR | |
| NPPES Provider FirstName | ALI | |
| NPPES Provider ZIPCode | 402021840 | |
| NPPES Provider State | KY | |
| Specialty Description | Neurology | |
| Total Claim Count | 201.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1063426971 |
| Last Name Of The Provider | CHOUCAIR |
| First Name Of The Provider | ALI |
| View All |
Similar Doctors
|
Dr. George W. Scott II, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Eric Burton, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Jason M. Meckler, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Madhuri V. Vallabhuni, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Michael K. Sowell, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Miles Evans, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tracy M. Ander, DO |
|
Dr. Kristi M. Nord, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Angela M. Hardwick, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Tad D. Seifert, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gaurav P. Dighe, MD |